What is Insight Molecular Diagnostics Inc.'s earnings per share (EPS)?

Insight Molecular Diagnostics Inc. (IMDX) reported diluted earnings per share of $-1.65 for fiscal year 2025. This represents a 64.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Insight Molecular Diagnostics Inc. Financials

IMDX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Insight Molecular Diagnostics Inc. (IMDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 29/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Insight Molecular Diagnostics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Insight Molecular Diagnostics Inc. has an operating margin of -1260.8%, meaning the company retains $-1261 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -3245.1% the prior year.

Growth

100

Insight Molecular Diagnostics Inc.'s revenue surged 115.6% year-over-year to $4.1M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Insight Molecular Diagnostics Inc. has a moderate D/E ratio of -1.82. This balance of debt and equity financing earns a leverage score of 53/100.

Liquidity

Insight Molecular Diagnostics Inc.'s current ratio of 1.27 is below the typical benchmark, resulting in a score of 21/100. However, the company holds substantial cash reserves (96% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow

While Insight Molecular Diagnostics Inc. generated -$22.2M in operating cash flow, capex of $3.2M consumed most of it, leaving -$25.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Insight Molecular Diagnostics Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.44x

For every $1 of reported earnings, Insight Molecular Diagnostics Inc. generates $0.44 in operating cash flow (-$22.2M OCF vs -$50.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-469.0x

Insight Molecular Diagnostics Inc. earns $-469.0 in operating income for every $1 of interest expense (-$51.1M vs $109K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.1M

YoY+115.6%

5Y CAGR+27.2%

Insight Molecular Diagnostics Inc. generated $4.1M in revenue in fiscal year 2025. This represents an increase of 115.6% from the prior year.

EBITDA

-$48.9M

YoY+17.7%

Insight Molecular Diagnostics Inc.'s EBITDA was -$48.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.7% from the prior year.

Net Income

-$50.2M

YoY+17.2%

Insight Molecular Diagnostics Inc. reported -$50.2M in net income in fiscal year 2025. This represents an increase of 17.2% from the prior year.

EPS (Diluted)

$-1.65

YoY+64.6%

Insight Molecular Diagnostics Inc. earned $-1.65 per diluted share (EPS) in fiscal year 2025. This represents an increase of 64.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$25.4M

YoY-19.6%

Insight Molecular Diagnostics Inc. generated -$25.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 19.6% from the prior year.

Cash & Debt

$11.6M

YoY+34.1%

5Y CAGR+10.2%

10Y CAGR+46.3%

Insight Molecular Diagnostics Inc. held $11.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

29M

YoY+64.3%

Insight Molecular Diagnostics Inc. had 29M shares outstanding in fiscal year 2025. This represents an increase of 64.3% from the prior year.

Margins & Returns

Gross Margin

56.7%

YoY+17.3pp

5Y CAGR+109.2pp

Insight Molecular Diagnostics Inc.'s gross margin was 56.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 17.3 percentage points from the prior year.

Operating Margin

-1260.8%

YoY+1984.4pp

5Y CAGR+1182.6pp

Insight Molecular Diagnostics Inc.'s operating margin was -1260.8% in fiscal year 2025, reflecting core business profitability. This is up 1984.4 percentage points from the prior year.

Net Margin

-1238.5%

YoY+1986.5pp

5Y CAGR+1223.0pp

Insight Molecular Diagnostics Inc.'s net profit margin was -1238.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1986.5 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$15.9M

YoY+61.6%

5Y CAGR+10.2%

10Y CAGR+14.9%

Insight Molecular Diagnostics Inc. invested $15.9M in research and development in fiscal year 2025. This represents an increase of 61.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3.2M

YoY+517.2%

5Y CAGR+21.0%

10Y CAGR+79.8%

Insight Molecular Diagnostics Inc. invested $3.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 517.2% from the prior year.

IMDX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.1M+115.6%	$1.9M+25.1%	$1.5M+56.9%	$958K-56.4%	$2.2M+80.8%	$1.2M
Cost of Revenue	$1.8M+66.2%	$1.1M+5.1%	$1.0M+13.9%	$880K+26.3%	$697K-62.4%	$1.9M
Gross Profit	$2.3M+210.5%	$740K+79.2%	$413K+429.5%	$78K-94.5%	$1.4M+322.2%	-$639K
R&D Expenses	$15.9M+61.6%	$9.8M+5.9%	$9.3M+27.3%	$7.3M+45.0%	$5.0M-48.6%	$9.8M
SG&A Expenses	$10.6M+4.2%	$10.2M-8.7%	$11.2M-48.9%	$21.9M-1.8%	$22.3M+32.8%	$16.8M
Operating Income	-$51.1M+16.2%	-$61.0M-142.8%	-$25.1M-39.7%	-$18.0M+66.5%	-$53.7M-80.8%	-$29.7M
Interest Expense	-$109K-29.8%	-$84K-61.5%	-$52K+37.3%	-$83K+60.3%	-$209K+17.1%	-$252K
Income Tax	$0	$0	$0	N/A	-$9.3M-638.5%	-$1.3M
Net Income	-$50.2M+17.2%	-$60.7M-118.4%	-$27.8M+61.9%	-$72.9M-13.7%	-$64.1M-114.1%	-$29.9M
EPS (Diluted)	$-1.65+64.6%	$-4.66-24.3%	$-3.75+71.7%	$-13.25	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.1M+338.1%	$260K-49.8%	$518K-75.8%	$2.1M+43.9%	$1.5M+1192.2%	$115K+10.6%	$104K-40.9%	$176K
Cost of Revenue	$655K+441.3%	$121K-28.0%	$168K-79.2%	$806K-7.2%	$869K+1920.9%	$43K+34.4%	$32K-70.6%	$109K
Gross Profit	$484K+248.2%	$139K-60.3%	$350K-73.6%	$1.3M+122.7%	$595K+1090.0%	$50K0.0%	$50K+11.1%	$45K
R&D Expenses	$5.8M+50.0%	$3.9M+18.2%	$3.3M+12.2%	$2.9M+29.6%	$2.3M-19.9%	$2.8M+14.8%	$2.5M+6.1%	$2.3M
SG&A Expenses	$2.3M-8.6%	$2.5M-3.9%	$2.6M-15.0%	$3.1M+21.7%	$2.6M-0.2%	$2.6M+6.6%	$2.4M-10.0%	$2.7M
Operating Income	-$23.4M-112.1%	-$11.0M-12.3%	-$9.8M-44.8%	-$6.8M+79.8%	-$33.6M-148.8%	-$13.5M-191.8%	-$4.6M+50.0%	-$9.3M
Interest Expense	-$26K+10.3%	-$29K-16.0%	-$25K+13.8%	-$29K+3.3%	-$30K+3.2%	-$31K-287.5%	-$8K+46.7%	-$15K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$23.0M-111.5%	-$10.9M-11.4%	-$9.7M-46.0%	-$6.7M+80.1%	-$33.5M-148.4%	-$13.5M-197.9%	-$4.5M+50.4%	-$9.1M
EPS (Diluted)	N/A	$-0.34-13.3%	$-0.30-15.4%	$-0.26	N/A	$-0.98-172.2%	$-0.36+68.1%	$-1.13

IMDX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$25.8M-26.6%	$35.1M-53.2%	$74.9M-25.2%	$100.1M-37.3%	$159.6M+187.9%	$55.4M
Current Assets	$15.3M+30.2%	$11.8M+9.9%	$10.7M-58.1%	$25.5M-34.8%	$39.1M+324.3%	$9.2M
Cash & Equivalents	$11.6M+34.1%	$8.6M-8.4%	$9.4M-52.8%	$20.0M-39.3%	$32.9M+361.3%	$7.1M
Inventory	$446K+8.8%	$410K	N/A	N/A	N/A	N/A
Accounts Receivable	$1.1M-30.1%	$1.6M+233.3%	$484K-75.9%	$2.0M+40.0%	$1.4M+607.9%	$203K
Goodwill	N/A	N/A	N/A	N/A	$18.7M+103.4%	$9.2M
Total Liabilities	$57.2M+20.8%	$47.4M-3.9%	$49.3M-18.5%	$60.5M-35.9%	$94.3M+330.1%	$21.9M
Current Liabilities	$12.1M+66.0%	$7.3M+1.1%	$7.2M-40.6%	$12.1M-14.3%	$14.1M+57.0%	$9.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$31.5M-156.3%	-$12.3M-160.0%	$20.5M-40.3%	$34.3M-47.4%	$65.2M+94.8%	$33.5M
Retained Earnings	-$400.8M-14.3%	-$350.5M-20.9%	-$289.9M-11.2%	-$260.7M-38.8%	-$187.8M-51.8%	-$123.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$25.8M-41.4%	$43.9M-13.0%	$50.5M-16.3%	$60.4M+72.1%	$35.1M-50.0%	$70.2M-6.0%	$74.7M+5.3%	$71.0M
Current Assets	$15.3M-28.4%	$21.4M-20.3%	$26.8M-26.0%	$36.3M+208.4%	$11.8M+145.3%	$4.8M-51.9%	$10.0M+52.5%	$6.5M
Cash & Equivalents	$11.6M-38.0%	$18.7M-23.0%	$24.3M-21.7%	$31.0M+259.3%	$8.6M+156.8%	$3.4M-63.7%	$9.3M+65.9%	$5.6M
Inventory	$446K-5.3%	$471K-32.0%	$693K+51.0%	$459K+12.0%	$410K+76.7%	$232K	N/A	N/A
Accounts Receivable	$1.1M+337.2%	$258K-49.6%	$512K-85.5%	$3.5M+119.5%	$1.6M+671.8%	$209K+145.9%	$85K-47.2%	$161K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$57.2M+7.7%	$53.1M+7.5%	$49.4M-1.4%	$50.1M+5.9%	$47.4M-21.7%	$60.5M+16.3%	$52.0M-3.8%	$54.1M
Current Liabilities	$12.1M+57.6%	$7.7M+15.2%	$6.7M-31.3%	$9.7M+33.1%	$7.3M-20.0%	$9.1M+26.3%	$7.2M-13.6%	$8.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$31.5M-242.1%	-$9.2M-937.5%	$1.1M-89.3%	$10.2M+183.2%	-$12.3M-226.4%	$9.7M-57.2%	$22.7M+95.9%	$11.6M
Retained Earnings	-$400.8M-6.1%	-$377.8M-3.0%	-$367.0M-2.7%	-$357.2M-1.9%	-$350.5M-10.6%	-$317.0M-4.4%	-$303.5M-1.5%	-$299.0M

IMDX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$22.2M-7.2%	-$20.7M+11.3%	-$23.3M+48.8%	-$45.6M-26.8%	-$35.9M-38.3%	-$26.0M
Capital Expenditures	$3.2M+517.2%	$516K+83.6%	$281K-93.5%	$4.3M+93.1%	$2.2M+83.1%	$1.2M
Free Cash Flow	-$25.4M-19.6%	-$21.2M+10.2%	-$23.6M+52.7%	-$49.9M-30.7%	-$38.2M-40.4%	-$27.2M
Investing Cash Flow	-$3.2M-522.1%	-$512K+45.1%	-$932K+78.5%	-$4.3M+68.9%	-$14.0M-18.8%	-$11.7M
Financing Cash Flow	$28.1M+37.4%	$20.4M+67.6%	$12.2M-66.0%	$35.8M-54.3%	$78.4M+243.7%	$22.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$5.5M-23.2%	-$4.5M+28.3%	-$6.3M-7.2%	-$5.9M-9.5%	-$5.4M+3.2%	-$5.5M+7.5%	-$6.0M-56.1%	-$3.8M
Capital Expenditures	$1.5M+40.9%	$1.1M+200.9%	$349K+13.7%	$307K+43.5%	$214K+146.0%	$87K-54.5%	$191K+695.8%	$24K
Free Cash Flow	-$7.0M-26.5%	-$5.6M+16.2%	-$6.6M-7.5%	-$6.2M-10.8%	-$5.6M+0.9%	-$5.6M+8.9%	-$6.2M-60.1%	-$3.9M
Investing Cash Flow	-$1.5M-40.9%	-$1.1M-200.9%	-$349K-13.7%	-$307K-46.2%	-$210K-141.4%	-$87K+54.5%	-$191K-695.8%	-$24K
Financing Cash Flow	-$252K-110.0%	-$120K-5.3%	-$114K-100.4%	$28.6M+163.5%	$10.8M+4349.8%	-$255K-102.6%	$9.8M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMDX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	56.7%+17.3pp	39.3%+11.9pp	27.5%+19.3pp	8.1%-56.5pp	64.6%+117.2pp	-52.5%
Operating Margin	-1260.8%+1984.4pp	-3245.1%-1572.8pp	-1672.4%+206.2pp	-1878.6%+565.7pp	-2444.3%-0.9pp	-2443.3%
Net Margin	-1238.5%+1986.5pp	-3225.0%-1376.7pp	-1848.4%+5761.4pp	-7609.8%-4693.7pp	-2916.2%-454.6pp	-2461.5%
Return on Equity	N/A	N/A	-135.7%+76.9pp	-212.6%-114.3pp	-98.3%-8.9pp	-89.4%
Return on Assets	-195.0%-22.1pp	-172.9%-135.8pp	-37.1%+35.8pp	-72.8%-32.7pp	-40.2%+13.8pp	-54.0%
Current Ratio	1.27-0.3	1.62+0.1	1.49-0.6	2.11-0.7	2.77+1.7	1.03
Debt-to-Equity	-1.82+2.0	-3.86-6.3	2.41+0.6	1.76+0.3	1.45+0.8	0.66
FCF Margin	-625.6%+501.7pp	-1127.3%+443.3pp	-1570.6%+3639.0pp	-5209.6%-3472.2pp	-1737.4%+500.0pp	-2237.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	42.5%-11.0pp	53.5%-14.1pp	67.6%+5.6pp	62.0%+21.9pp	40.0%-3.4pp	43.5%-4.6pp	48.1%+22.5pp	25.6%
Operating Margin	-2057.5%+2191.7pp	-4249.2%-2349.2pp	-1900.0%-1582.0pp	-318.0%+1944.9pp	-2262.9%+9489.3pp	-11752.2%-7298.3pp	-4453.9%+811.5pp	-5265.3%
Net Margin	-2015.4%+2159.3pp	-4174.6%-2293.9pp	-1880.7%-1568.7pp	-312.0%+1943.1pp	-2255.1%+9477.9pp	-11733.0%-7377.3pp	-4355.8%+831.2pp	-5186.9%
Return on Equity	N/A	N/A	-887.3%-822.0pp	-65.3%	N/A	-138.9%-119.0pp	-20.0%+58.8pp	-78.8%
Return on Assets	-89.1%-64.4pp	-24.7%-5.4pp	-19.3%-8.2pp	-11.1%+84.5pp	-95.5%-76.3pp	-19.2%-13.2pp	-6.1%+6.8pp	-12.9%
Current Ratio	1.27-1.5	2.79-1.2	4.04+0.3	3.75+2.1	1.62+1.1	0.53-0.9	1.38+0.6	0.78
Debt-to-Equity	-1.82+4.0	-5.78-50.8	45.01+40.1	4.91+8.8	-3.86-10.1	6.23+3.9	2.29-2.4	4.66
FCF Margin	-616.7%+1518.7pp	-2135.4%-855.8pp	-1279.5%-991.2pp	-288.4%+86.1pp	-374.5%+4509.9pp	-4884.3%+1047.4pp	-5931.7%-3742.0pp	-2189.8%

Note: Shareholder equity is negative (-$31.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Burning Rock Biotech Ltd BNR

$222.5M

$118.5M

$300.9M

$132.8M

$118.7M

Frequently Asked Questions

What is Insight Molecular Diagnostics Inc.'s annual revenue?

Insight Molecular Diagnostics Inc. (IMDX) reported $4.1M in total revenue for fiscal year 2025. This represents a 115.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Insight Molecular Diagnostics Inc.'s revenue growing?

Insight Molecular Diagnostics Inc. (IMDX) revenue grew by 115.6% year-over-year, from $1.9M to $4.1M in fiscal year 2025.

Is Insight Molecular Diagnostics Inc. profitable?

No, Insight Molecular Diagnostics Inc. (IMDX) reported a net income of -$50.2M in fiscal year 2025, with a net profit margin of -1238.5%.

What is Insight Molecular Diagnostics Inc.'s EBITDA?

Insight Molecular Diagnostics Inc. (IMDX) had EBITDA of -$48.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Insight Molecular Diagnostics Inc.'s gross margin?

Insight Molecular Diagnostics Inc. (IMDX) had a gross margin of 56.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Insight Molecular Diagnostics Inc.'s operating margin?

Insight Molecular Diagnostics Inc. (IMDX) had an operating margin of -1260.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Insight Molecular Diagnostics Inc.'s net profit margin?

Insight Molecular Diagnostics Inc. (IMDX) had a net profit margin of -1238.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Insight Molecular Diagnostics Inc.'s free cash flow?

Insight Molecular Diagnostics Inc. (IMDX) generated -$25.4M in free cash flow during fiscal year 2025. This represents a -19.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Insight Molecular Diagnostics Inc.'s operating cash flow?

Insight Molecular Diagnostics Inc. (IMDX) generated -$22.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Insight Molecular Diagnostics Inc.'s total assets?

Insight Molecular Diagnostics Inc. (IMDX) had $25.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Insight Molecular Diagnostics Inc.'s capital expenditures?

Insight Molecular Diagnostics Inc. (IMDX) invested $3.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Insight Molecular Diagnostics Inc. spend on research and development?

Insight Molecular Diagnostics Inc. (IMDX) invested $15.9M in research and development during fiscal year 2025.

How many shares does Insight Molecular Diagnostics Inc. have outstanding?

Insight Molecular Diagnostics Inc. (IMDX) had 29M shares outstanding as of fiscal year 2025.

What is Insight Molecular Diagnostics Inc.'s current ratio?

Insight Molecular Diagnostics Inc. (IMDX) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.

What is Insight Molecular Diagnostics Inc.'s debt-to-equity ratio?

Insight Molecular Diagnostics Inc. (IMDX) had a debt-to-equity ratio of -1.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Insight Molecular Diagnostics Inc.'s return on assets (ROA)?

Insight Molecular Diagnostics Inc. (IMDX) had a return on assets of -195.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Insight Molecular Diagnostics Inc.'s cash runway?

Based on fiscal year 2025 data, Insight Molecular Diagnostics Inc. (IMDX) had $11.6M in cash against an annual operating cash burn of $22.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Insight Molecular Diagnostics Inc.'s debt-to-equity ratio negative or unusual?

Insight Molecular Diagnostics Inc. (IMDX) has negative shareholder equity of -$31.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Insight Molecular Diagnostics Inc.'s Piotroski F-Score?

Insight Molecular Diagnostics Inc. (IMDX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Insight Molecular Diagnostics Inc.'s earnings high quality?

Insight Molecular Diagnostics Inc. (IMDX) has an earnings quality ratio of 0.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Insight Molecular Diagnostics Inc. cover its interest payments?

Insight Molecular Diagnostics Inc. (IMDX) has an interest coverage ratio of -469.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Insight Molecular Diagnostics Inc.?

Insight Molecular Diagnostics Inc. (IMDX) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.